ABSTRACT
As it has been shown that lopinavir (LPV) and hydroxychloroquine (HCQ) have in vitro activity against coronaviruses, they were used to treat COVID-19 during the first wave of the epidemic in Lombardy, Italy.
The aim of this retrospective intent-to-treat analysis of the hospitalized patients who started off-label treatment with LPV/ritonavir (LPV/r)+HCQ between 21 February and 20 March 2020 was to compare the rate of clinical improvement between those who started the treatment within five days of symptom onset (early treatment, ET) and those who started later (delayed treatment, DT). The association between the timing of treatment and the probability of 30-day mortality was also assessed using uni- and multivariable logistic models.
The study involved 172 patients: 43 (25%) in the ET and 129 (75%) in the DT group. The rate of clinical improvement increased over time to 73.3% on day 30, without any significant difference between the two groups (Gray’s test P = 0.213). After adjusting for potentially relevant clinical variables, there was no significant association between the timing of the start of treatment and the probability of 30-day mortality (adjusted odds ratio [aOR] ET vs DT = 1.45, 95% confidence interval 0.50-4.19). Eight percent of the patients discontinued the treatment because of severe gastrointestinal disorders attributable to LPV/r.
The timing of the start of LPV/r+HCQ treatment does not seem to affect the clinical course of hospitalised patients with COVID-19. Together with the severe adverse events attributable to LPV/r, this raises concerns about the benefit of using this combination to treat COVID-19.
Competing Interest Statement
AG received consultancy fees from Mylan and non-financial educational support from Gilead. SR received grants, fees for speaker's bureau, advisory boards and CME activities from BMS, ViiV, MSD, AbbVie, Gilead, Janssen. MG received grants, fees for speaker's bureau, advisory boards and CME activities from BMS, ViiV, MSD, AbbVie, Gilead, Janssen and Roche. GR received grants, fees for speaker's bureau, advisory boards and CME activities from BMS, ViiV, MSD, AbbVie, Gilead, Janssen and Roche. SA received support for research activities from Pfizer and Merck Sharp & Dome. GP, LO, CB, FC, LP, LB, SP, AT, GC, VM, PS, CC, EC, AMB, RC, MC, GG have nothing to declare.
Funding Statement
The study was not funded.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by our Comitato Etico Interaziendale Area 1. Al patients signed a written informed consent for the off-label treatment with lopinavir/ritonavir and hydroxychloroquine. Informed consent was waived in the case of patients undergoing mechanical ventilation upon admission.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
- CCI
- Charlson Comorbidity Index
- ET
- early treatment group
- DT
- delayed treatment group
- paO2
- partial oxygen pressure
- D-d
- D-dimer
- NA
- not assigned
- CRP
- C-reactive protein
- aOR
- adjusted odds ratio
- Log
- logarithmic.
LIST OF ABBREVIATIONS
- COVID-19
- coronavirus induced disease
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus 2
- ET
- early treatment
- DT
- delayed treatment
- HCoV-229E
- Human coronavirus 229E
- TNF-1
- Tumor necrosis factor 1
- IL-6
- interleukin 6
- MERS
- Middle Eastern Respiratory Syndrome Coronavirus
- LPV/r
- lopinavir/ritonavir
- HCQ
- hydroxychloroquine
- SIMIT
- Società Italina di Malattie Infettive e Tropicali
- RT-PCR
- real time polymerase chain reaction
- SpO2
- percutaneous oxygen saturation
- CCI
- Charlson comorbidity index
- FiO2
- fraction of inspired oxygen
- PaO2
- arterial partial pressure of oxygen
- IQR
- inter quartile range
- ICU
- intensive care unit
- ECMO
- Extra corporeal membrane oxygenation
- CRP
- C-reactive protein
- OR
- Odds Ratio
- aOR
- adjusted Odds Ratio
- CI
- Confidence Interval
- AE
- Adverse Events
- PA-IC90
- protein-adjusted 90% inhibitory concentration
- ELF
- epithelial lining fluid
- CSF
- cerebrospinal fluid
